奥密克戎为关切变异株期间妊娠结局与疫苗有效性:INTERCOVID-2022 多国观察性研究
INTERCOVID-2022 是一项前瞻性观察性研究,纳入 18 个国家 41 家医院的 4618 名孕妇,从 2021 年 11 月 27 日(WHO 宣布奥密克戎为关切变异株次日)至 2022 年 6 月 30 日,比较实验室确诊 COVID-19 孕妇(1545 例,33%)与无 COVID-19 诊断孕妇(3073 例,67%)的母婴结局。确诊孕妇 MMMI 风险升高(RR 1.16,95%CI 1.03-1.31),SPMMI 风险升高(RR 1.21,95%CI 1.00-1.46),SNMI 风险升高但 95%CI 下限跨 1(RR 1.23,95%CI 0.88-1.71)。未接种疫苗且确诊者 MMMI 风险更高(RR 1.36,95%CI 1.12-1.65)。全程接种疫苗对 COVID-19 严重并发症的有效性为 48%(95%CI 22-65),加强接种后为 76%(95%CI 47-89)。作者认为妊娠期 COVID-19 与严重孕产妇发病和死亡风险增加相关,疫苗接种覆盖率仍是优先事项。
要点
- 奥密克戎为关切变异株期间,妊娠期 COVID-19 确诊者 MMMI 风险升高(RR 1.16,95%CI 1.03-1.31),SPMMI 风险升高(RR 1.21,95%CI 1.00-1.46)。
- 未接种疫苗且确诊 COVID-19 的孕妇 MMMI 风险更高(RR 1.36,95%CI 1.12-1.65)。
- 总样本中严重 COVID-19 症状增加严重孕产妇并发症风险(RR 2.51,95%CI 1.84-3.43)、围产期并发症风险(RR 1.84,95%CI 1.02-3.34)以及转诊、ICU 入住或死亡风险(RR 11.83,95%CI 6.67-20.97)。
- 未接种疫苗女性中严重 COVID-19 症状增加 MMMI 风险(RR 2.88,95%CI 2.02-4.12)和转诊、ICU 入住或死亡风险(RR 20.82,95%CI 10.44-41.54)。
- 所有疫苗合并计算,全程接种对 COVID-19 严重并发症的有效性为 48%(95%CI 22-65),加强接种后为 76%(95%CI 47-89);确诊 COVID-19 女性中全程接种有效性为 74%(95%CI 48-87),加强接种后为 91%(95%CI 65-98)。
适用人群与场景
- 2021年11月27日至2022年6月30日期间在18个国家41家医院招募的孕妇,实时PCR或快速检测实验室确诊COVID-19者与同期连续招募的无COVID-19诊断孕妇按1:2不匹配比较,随访至出院。
诊断标准与关键阈值
- COVID-19诊断依据实时PCR或快速检测实验室确认。
- 主要结局指标:MMMI(孕产妇发病与死亡指数)、SNMI(严重新生儿发病指数)、SPMMI(严重围产期发病与死亡指数)。
红旗征与不能漏的情况
- 严重COVID-19症状增加严重孕产妇并发症(RR 2.51,95%CI 1.84-3.43)、围产期并发症(RR 1.84,95%CI 1.02-3.34)及转诊、ICU入住或死亡(RR 11.83,95%CI 6.67-20.97)风险。
- 未接种疫苗女性中严重COVID-19症状增加MMMI风险(RR 2.88,95%CI 2.02-4.12)及转诊、ICU入住或死亡风险(RR 20.82,95%CI 10.44-41.54)。
研究设计与关键结果
- INTERCOVID-2022为前瞻性观察性研究,纳入18个国家41家医院的4618名孕妇,其中1545名(33%)确诊COVID-19(中位孕周36.7周,IQR 29.0-38.9),3073名(67%)无COVID-19诊断且人口学特征相似。
- 确诊孕妇MMMI风险升高(RR 1.16,95%CI 1.03-1.31),SPMMI风险升高(RR 1.21,95%CI 1.00-1.46),SNMI风险升高但95%CI下限跨1(RR 1.23,95%CI 0.88-1.71)。
- 未接种疫苗且确诊COVID-19者MMMI风险更高(RR 1.36,95%CI 1.12-1.65)。
- 总样本中严重COVID-19症状增加严重孕产妇并发症风险(RR 2.51,95%CI 1.84-3.43)、围产期并发症风险(RR 1.84,95%CI 1.02-3.34)及转诊、ICU入住或死亡风险(RR 11.83,95%CI 6.67-20.97)。
- 未接种疫苗女性中严重COVID-19症状增加MMMI风险(RR 2.88,95%CI 2.02-4.12)及转诊、ICU入住或死亡风险(RR 20.82,95%CI 10.44-41.54)。
- 4618名参与者中2886名(63%)至少接种一剂任何疫苗,2476名(54%)完成全程或加强接种。
- 所有疫苗合并计算,全程接种对COVID-19严重并发症的有效性为48%(95%CI 22-65),加强接种后为76%(95%CI 47-89);确诊COVID-19女性中全程接种有效性为74%(95%CI 48-87),加强接种后为91%(95%CI 65-98)。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究(INTERCOVID-2022),多国多中心。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,妊娠期COVID-19在奥密克戎为关切变异株的头6个月与严重孕产妇发病和死亡风险增加相关,尤其是有症状和未接种疫苗的女性。
- 作者认为,完成疫苗全程或加强接种的女性严重症状、并发症和死亡风险降低。
- 作者认为,提高孕妇疫苗接种覆盖率仍是优先事项。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In 2021, we showed an increased risk associated with COVID-19 in pregnancy. Since then, the SARS-CoV-2 virus has undergone genetic mutations. We aimed to examine the effects on maternal and perinatal outcomes of COVID-19 during pregnancy, and evaluate vaccine effectiveness, when omicron (B.1.1.529) was the variant of concern.
METHODS: INTERCOVID-2022 is a large, prospective, observational study, involving 41 hospitals across 18 countries. Each woman with real-time PCR or rapid test, laboratory-confirmed COVID-19 in pregnancy was compared with two unmatched women without a COVID-19 diagnosis who were recruited concomitantly and consecutively in pregnancy or at delivery. Mother and neonate dyads were followed until hospital discharge. Primary outcomes were maternal morbidity and mortality index (MMMI), severe neonatal morbidity index (SNMI), and severe perinatal morbidity and mortality index (SPMMI). Vaccine effectiveness was estimated, adjusted by maternal risk profile.
FINDINGS: We enrolled 4618 pregnant women from Nov 27, 2021 (the day after WHO declared omicron a variant of concern), to June 30, 2022: 1545 (33%) women had a COVID-19 diagnosis (median gestation 36·7 weeks [IQR 29·0-38·9]) and 3073 (67%) women, with similar demographic characteristics, did not have a COVID-19 diagnosis. Overall, women with a diagnosis had an increased risk for MMMI (relative risk [RR] 1·16 [95% CI 1·03-1·31]) and SPMMI (RR 1·21 [95% CI 1·00-1·46]). Women with a diagnosis, compared with those without a diagnosis, also had increased risks of SNMI (RR 1·23 [95% CI 0·88-1·71]), although the lower bounds of the 95% CI crossed unity. Unvaccinated women with a COVID-19 diagnosis had a greater risk of MMMI (RR 1·36 [95% CI 1·12-1·65]). Severe COVID-19 symptoms in the total sample increased the risk of severe maternal complications (RR 2·51 [95% CI 1·84-3·43]), perinatal complications (RR 1·84 [95% CI 1·02-3·34]), and referral, intensive care unit (ICU) admission, or death (RR 11·83 [95% CI 6·67-20·97]). Severe COVID-19 symptoms in unvaccinated women increased the risk of MMMI (RR 2·88 [95% CI 2·02-4·12]) and referral, ICU admission, or death (RR 20·82 [95% CI 10·44-41·54]). 2886 (63%) of 4618 total participants had at least a single dose of any vaccine, and 2476 (54%) of 4618 had either complete or booster doses. Vaccine effectiveness (all vaccines combined) for severe complications of COVID-19 for all women with a complete regimen was 48% (95% CI 22-65) and 76% (47-89) after a booster dose. For women with a COVID-19 diagnosis, vaccine effectiveness of all vaccines combined for women with a complete regimen was 74% (95% CI 48-87) and 91% (65-98) after a booster dose.
INTERPRETATION: COVID-19 in pregnancy, during the first 6 months of omicron as the variant of concern, was associated with increased risk of severe maternal morbidity and mortality, especially among symptomatic and unvaccinated women. Women with complete or boosted vaccine doses had reduced risk for severe symptoms, complications, and death. Vaccination coverage among pregnant women remains a priority.
参考来源
- Villar J, Soto Conti CP, Gunier RB, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. 2023. PMID: 36669520. doi:10.1016/S0140-6736(22)02467-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。